US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

10.68

-1.3800-11.44%

Post-market: 10.680.00000.00%18:43 EDT

Volume:2.57M

Turnover:27.99M

Market Cap:1.47B

PE:-2.07

High:11.96

Open:11.74

Low:10.66

Close:12.06

Loading ...

Overview Company News Filings

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses

Simply Wall St.

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Arrowhead data supports blockbuster potential of ARO-C3, says H.C. Wainwright

Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements

Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients

MT Newswires Live

BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy

Arrowhead announces topline results from ARO-C3 trial

Arrowhead Pharmaceuticals Inc - Aro-C3 Generally Well-Tolerated in Patients With Igan

THOMSON REUTERS

Arrowhead Pharmaceuticals Announces Topline Results From Part 2 of Phase 1/2 Study of Aro-C3 in Patients With Iga Nephropathy

THOMSON REUTERS

Arrowhead Pharmaceuticals Inc - No Serious or Severe Treatment Emergent Adverse Events Reported

THOMSON REUTERS

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment

MT Newswires Live

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead presents preclinical results on ARO-ALK7

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals Price Target Cut to $38.00/Share From $51.00 by B. Riley Securities

B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARWR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARWR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARWR\",,,,,undefined,":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Pharmaceuticals","latestPrice":10.68,"timestamp":1743796800000,"preClose":12.06,"halted":0,"volume":2565519,"hourTrading":{"tag":"盘后","latestPrice":10.68,"preClose":10.68,"latestTime":"18:43 EDT","volume":24511,"amount":266927.61,"timestamp":1743806632893},"delay":0,"floatShares":119000000,"shares":137317373,"eps":-5.153072,"marketStatus":"Market Closed","change":-1.38,"latestTime":"04-04 16:00:00 EDT","open":11.74,"high":11.96,"low":10.655,"amount":27993298.830321,"amplitude":0.108209,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.153072,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":12.06,"preHourTrading":{"tag":"盘前","latestPrice":12,"preClose":12.06,"latestTime":"08:00 EDT","volume":50,"amount":600,"timestamp":1743768000531},"postHourTrading":{"tag":"盘后","latestPrice":10.68,"preClose":10.68,"latestTime":"18:43 EDT","volume":24511,"amount":266927.61,"timestamp":1743806632893},"volumeRatio":1.3484045588688978,"impliedVol":1.3098,"impliedVolPercentile":0.988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARWR\",,,,,undefined,":{"symbol":"ARWR","floatShares":119000000,"roa":"-47.71%","roe":"-565.33%","lyrEps":-5.004783,"volumeRatio":1.3484045588688978,"shares":137317373,"dividePrice":0,"high":11.96,"amplitude":0.108209,"preClose":12.06,"low":10.655,"week52Low":10.655,"pbRate":"27.89","psRate":"586.62","week52High":30.41,"institutionHeld":0.9542,"latestPrice":10.68,"eps":-5.153072,"divideRate":0,"volume":2565519,"delay":0,"ttmEps":-5.153072,"open":11.74,"prevYearClose":18.8,"prevWeekClose":13.82,"prevMonthClose":12.74,"prevQuarterClose":12.74,"fiveDayClose":13.82,"twentyDayClose":16.97,"sixtyDayClose":19.67},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARWR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525307197","title":"Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525307197","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525307197?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:30","pubTimestamp":1743798600,"startTime":"0","endTime":"0","summary":"PASADENA, Calif., April 04, 2025----Arrowhead Pharmaceuticals, Inc.  today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company’s Board of Directors approved \"inducement\" grants to 21 new employees under Rule 5635 of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest annually over four years.Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-reports-inducement-grants-203000518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112",".IXIC","LU2095319765.USD","NDAQ","ARWR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","BK4139"],"gpt_icon":0},{"id":"2518278188","title":"Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278188","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518278188?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:04","pubTimestamp":1741629841,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Arrowhead Pharmaceuticals' stock price is sensitive to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/institutional-investors-may-adopt-severe-steps-after-arrowhe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARWR",".IXIC","NDAQ"],"gpt_icon":0},{"id":"2518206234","title":"Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206234","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206234?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:02","pubTimestamp":1741629721,"startTime":"0","endTime":"0","summary":"On Monday, Arrowhead Pharmaceuticals, Inc. released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference  therapeutic designed to reduce liver production of complement component 3  as a potential therapy for various complement-mediated diseases.ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.Also Read: Veren Soars On Whitecap Merger Deal: Details. The company plans to present additional results at a medical meeting in 2025.Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.Maximum mea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-stock-falls-early-180201122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARWR","BK4139","BK4505","SSI","BK4585","RNA","BK4588"],"gpt_icon":0},{"id":"2518277683","title":"Arrowhead data supports blockbuster potential of ARO-C3, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277683","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277683?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:20","pubTimestamp":1741623618,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line dat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-data-supports-blockbuster-potential-of-aro-c3-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-data-supports-blockbuster-potential-of-aro-c3-says-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","ARWR","BK4588"],"gpt_icon":0},{"id":"2518277662","title":"Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277662?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:15","pubTimestamp":1741623318,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-arrowhead-pharmaceuticals-driven-by-promising-aro-c3-trial-results-and-strategic-pipeline-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-arrowhead-pharmaceuticals-driven-by-promising-aro-c3-trial-results-and-strategic-pipeline-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARWR"],"gpt_icon":0},{"id":"2518216712","title":"Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2518216712","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518216712?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:12","pubTimestamp":1741612364,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases.The second part of the phase 1/2 clinical study also showed reductions of 85% in AH50 and 100% in Wieslab AP, which are both markers of alternative pathway complement activity, in patients with IgA nephropathy, the company said.Arrowhead also reported that the therapy was generally well tolerated by the patients, with no serious or severe treatment adverse events.The study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of adult healthy volunteers and adult patients with complement-mediated renal disease.The company said it plans to present additional results at an upcoming medical meeting later this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARWR","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2518240622","title":"BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240622","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240622?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:43","pubTimestamp":1741606996,"startTime":"0","endTime":"0","summary":"BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA NephropathyMarch 10 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:ARROWHEAD P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2518924031","title":"Arrowhead announces topline results from ARO-C3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2518924031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518924031?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:35","pubTimestamp":1741606520,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ther...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-topline-results-from-aro-c3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-announces-topline-results-from-aro-c3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4139","RNA","BK4505","ARWR"],"gpt_icon":0},{"id":"2518924715","title":"Arrowhead Pharmaceuticals Inc - Aro-C3 Generally Well-Tolerated in Patients With Igan","url":"https://stock-news.laohu8.com/highlight/detail?id=2518924715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518924715?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARWR","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2518247169","title":"Arrowhead Pharmaceuticals Announces Topline Results From Part 2 of Phase 1/2 Study of Aro-C3 in Patients With Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247169?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARWR","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2518247147","title":"Arrowhead Pharmaceuticals Inc - No Serious or Severe Treatment Emergent Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2518247147","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518247147?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606213,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","ARWR","BK4588"],"gpt_icon":0},{"id":"2518922845","title":"Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518922845","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518922845?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:30","pubTimestamp":1741606200,"startTime":"0","endTime":"0","summary":"- ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria. - Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24. - Mean reduction in spot urine protein-to-creatinine ratio  of 41% by week 24. PASADENA, Calif., March 10, 2025----Arrowhead Pharmaceuticals, Inc.  today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference  therapeutic designed to reduce liver production of complement component 3  as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025.Patients with IgA nephropathy   received subcutaneous doses of ARO-C3  on Days 1, 29, and 113 and were followed through Day 169. Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-announces-topline-results-113000429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARWR","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2517031165","title":"Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517031165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517031165?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:48","pubTimestamp":1741272537,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said Thursday it has presented preclinical data supporting two RNA-interference-based investigational therapeutics it is developing, with the potential to reduce body weight and fat mass and preserve lean muscle mass compared with currently approved obesity therapies.Data from its ARO-INHBE candidate preclinical results showed a 19% suppression in body weight gain relative to vehicle controls, while data from its ARO-ALK7 candidate preclinical results showed a 39% suppression, the company said.Arrowhead is currently conducting phase 1/2 clinical studies of the two candidates. The company expects initial data from its ARO-INHBE study year-end 2025, and anticipates dosing in the ARO-ALK7 study to begin in the second quarter with initial data from the single-ascending dose portion of the study possible also by year-end 2025.The company presented the data at the RNA Leaders Europe Congress 2025 held March 4-6 in Basel, Switzerland.Price: 16.89, Change: -0.46, Per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","SSI","ARWR","BK4139"],"gpt_icon":0},{"id":"2517716889","title":"Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2517716889","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517716889?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:45","pubTimestamp":1741268700,"startTime":"0","endTime":"0","summary":"- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. - Data highlight Arrowhead’s leadership in the use of RNA interference to potentially treat Obesity. DIO mice treated with an ALK7 siRNA exhibit a 39% suppression in body weight gain relative to controls. Adipose ALK7 silencing reduced fat mass by 50% while preserving lean mass. Similar to INHBE silencing in hepatocytes, ALK7 silencing in adipocytes enhanced catecholamine sensitivity, increasing lipid mobilization and oxidation, which was not associated with liver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-showcases-two-clinical-134500669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SSI","BK4588","BK4585","ARWR"],"gpt_icon":0},{"id":"2514229263","title":"Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (Fcs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514229263","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514229263?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA42KS62:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","ARWR","BK4588"],"gpt_icon":0},{"id":"2514327974","title":"Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514327974","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514327974?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"New Patient Resource Hub: Arrowhead expands its We’ll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides. Amplifying Patient Voices: The Spotlight on FCS white paper shares real patient experiences, highlighting the challenges of managing this ultra-rare disease and the need for greater awareness. Commitment to the FCS Community: On Rare Disease Day and beyond, Arrowhead remains dedicated to elevating patient voices and fostering community engagement. #ForFCS. PASADENA, Calif., February 28, 2025----Arrowhead Pharmaceuticals, Inc.  marks Rare Disease Day with the expansion of the We’ll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-launches-rare-disease-140000788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TG","BK4090","ARWR","BK4153","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2514099545","title":"Arrowhead presents preclinical results on ARO-ALK7","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099545?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:01","pubTimestamp":1740488474,"startTime":"0","endTime":"0","summary":"Arrowhead (ARWR) announced preclinical results on ARO-ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arrowhead-presents-preclinical-results-on-aro-alk7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arrowhead-presents-preclinical-results-on-aro-alk7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RNA","BK4139","BK4585","BK4588","ARWR"],"gpt_icon":0},{"id":"2514095256","title":"Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095256","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095256?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:30","pubTimestamp":1740486600,"startTime":"0","endTime":"0","summary":"PASADENA, Calif., February 25, 2025----Arrowhead Pharmaceuticals, Inc.  today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference  therapeutic targeting Activin receptor-like kinase 7  being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada.ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead’s leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule  platform. Arrowhead received regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7 in New Zealand, which the company anticipates will begin dosing in the second quarter of 2025.Single subcutaneous doses of ARO-ALK7 led to dose-dependent and durable reductions in ALK7 mRNA in abdom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-presents-preclinical-data-123000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","BK4585","ARWR"],"gpt_icon":0},{"id":"2511613486","title":"Arrowhead Pharmaceuticals Price Target Cut to $38.00/Share From $51.00 by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2511613486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511613486?lang=en_us&edition=fundamental","pubTime":"2025-02-15 01:50","pubTimestamp":1739555400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARWR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 14, 2025 12:50 ET (17:50 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RILY","ARWR"],"gpt_icon":0},{"id":"2511698681","title":"B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2511698681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511698681?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:33","pubTimestamp":1739540015,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR) has an average rating of overweight and mean price target of $41.42, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resear","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARWR","RILY"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":134}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARWR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-10","symbol":"ARWR","fiscalQuarterEnding":"2024/12","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739163600000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2024-11-26","symbol":"ARWR","fiscalQuarterEnding":"2024/09","expectedEps":-0.63,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-1.38},{"market":"US","date":"2024-08-08","symbol":"ARWR","fiscalQuarterEnding":"2024/06","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-1.38},{"market":"US","date":"2024-05-09","symbol":"ARWR","fiscalQuarterEnding":"2024/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2024-02-06","symbol":"ARWR","fiscalQuarterEnding":"2023/12","expectedEps":-0.78,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1707195600000,"reportTimeType":"post","actualEps":-1.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARWR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARWR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1333,"buy":0.5333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1717646400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARWR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARWR","date":"2025-04-04","current":-2.377224,"percent":0.931204,"low":-296.588514,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"high":547.43255,"avg":-17.354808,"sd":115.801719,"marketCap":1520743218},"quantilePoints":[{"date":"2020-04-09","current":64.640256,"twenty":-18.241176,"median":-4.331166,"eighty":-1.26618,"marketCap":3443037135},{"date":"2020-04-17","current":69.754986,"twenty":-18.275409,"median":-4.261219,"eighty":-1.126291,"marketCap":3715471134},{"date":"2020-04-24","current":74.220832,"twenty":-18.275409,"median":-4.206053,"eighty":-1.052527,"marketCap":3953342610},{"date":"2020-05-01","current":62.140146,"twenty":-18.275409,"median":-4.153652,"eighty":-1.026185,"marketCap":3309869771},{"date":"2020-05-08","current":364.527936,"twenty":-18.275409,"median":-4.13929,"eighty":41.608706,"marketCap":3474539574},{"date":"2020-05-15","current":382.786365,"twenty":-18.275409,"median":-4.132262,"eighty":49.925866,"marketCap":3648571872},{"date":"2020-05-22","current":381.077974,"twenty":-18.275409,"median":-4.111179,"eighty":53.834436,"marketCap":3632288149},{"date":"2020-05-29","current":344.240792,"twenty":-18.275409,"median":-4.077636,"eighty":55.242895,"marketCap":3281170353},{"date":"2020-06-05","current":363.780515,"twenty":-18.275409,"median":-4.040903,"eighty":57.04414,"marketCap":3467415445},{"date":"2020-06-12","current":349.47274,"twenty":-18.275409,"median":-4.02418,"eighty":58.828247,"marketCap":3331039258},{"date":"2020-06-19","current":392.182515,"twenty":-18.275409,"median":-3.992874,"eighty":60.10843,"marketCap":3738132354},{"date":"2020-06-26","current":462.012999,"twenty":-18.275409,"median":-3.957597,"eighty":60.495173,"marketCap":4403729565},{"date":"2020-07-02","current":471.943021,"twenty":-18.275409,"median":-3.92846,"eighty":61.039647,"marketCap":4498378710},{"date":"2020-07-10","current":475.253029,"twenty":-18.275409,"median":-3.891958,"eighty":61.895529,"marketCap":4529928425},{"date":"2020-07-17","current":523.408301,"twenty":-18.275409,"median":-3.871005,"eighty":62.625798,"marketCap":4988925891},{"date":"2020-07-24","current":493.404684,"twenty":-18.275409,"median":-3.843641,"eighty":64.1913,"marketCap":4702942991},{"date":"2020-07-31","current":459.87751,"twenty":-18.275409,"median":-3.801907,"eighty":65.132645,"marketCap":4383374911},{"date":"2020-08-07","current":-168.551432,"twenty":-18.529695,"median":-3.789176,"eighty":65.318147,"marketCap":4115199234},{"date":"2020-08-14","current":-176.00909,"twenty":-18.968112,"median":-3.789176,"eighty":65.318147,"marketCap":4297278644},{"date":"2020-08-21","current":-178.020143,"twenty":-19.299259,"median":-3.789176,"eighty":65.318147,"marketCap":4346378709},{"date":"2020-08-28","current":-175.841502,"twenty":-19.749926,"median":-3.789176,"eighty":65.318147,"marketCap":4293186971},{"date":"2020-09-04","current":-150.99661,"twenty":-20.156605,"median":-3.789176,"eighty":65.318147,"marketCap":3686596580},{"date":"2020-09-11","current":-139.139773,"twenty":-20.285462,"median":-3.789176,"eighty":65.318147,"marketCap":3397110777},{"date":"2020-09-18","current":-180.575857,"twenty":-20.45098,"median":-3.789176,"eighty":65.318147,"marketCap":4408776709},{"date":"2020-09-25","current":-188.180154,"twenty":-20.855341,"median":-3.789176,"eighty":65.318147,"marketCap":4594436331},{"date":"2020-10-02","current":-183.592438,"twenty":-21.000912,"median":-3.789176,"eighty":65.318147,"marketCap":4482426807},{"date":"2020-10-09","current":-192.935458,"twenty":-21.181622,"median":-3.789176,"eighty":65.318147,"marketCap":4710537528},{"date":"2020-10-16","current":-206.887142,"twenty":-21.519563,"median":-3.789176,"eighty":65.318147,"marketCap":5051169232},{"date":"2020-10-23","current":-246.689245,"twenty":-21.724568,"median":-3.789176,"eighty":65.318147,"marketCap":6022941360},{"date":"2020-10-30","current":-240.069527,"twenty":-21.896478,"median":-3.789176,"eighty":65.318147,"marketCap":5861320311},{"date":"2020-11-06","current":-278.405237,"twenty":-22.1947,"median":-3.789176,"eighty":65.318147,"marketCap":6797290309},{"date":"2020-11-13","current":-287.1617,"twenty":-22.423055,"median":-3.789176,"eighty":65.318147,"marketCap":7011080177},{"date":"2020-11-20","current":-288.25102,"twenty":-22.812061,"median":-3.789176,"eighty":65.318147,"marketCap":7037676046},{"date":"2020-11-27","current":-76.551382,"twenty":-23.016886,"median":-3.789176,"eighty":65.318147,"marketCap":6472649005},{"date":"2020-12-04","current":-79.346559,"twenty":-23.27504,"median":-3.789176,"eighty":65.318147,"marketCap":6708989578},{"date":"2020-12-11","current":-90.004689,"twenty":-23.443255,"median":-3.789176,"eighty":65.318147,"marketCap":7610166460},{"date":"2020-12-18","current":-97.417984,"twenty":-23.662829,"median":-3.789176,"eighty":65.318147,"marketCap":8236982763},{"date":"2020-12-24","current":-102.315619,"twenty":-23.828206,"median":-3.789176,"eighty":65.318147,"marketCap":8651092550},{"date":"2020-12-31","current":-93.249524,"twenty":-23.877135,"median":-3.789176,"eighty":65.318147,"marketCap":7884527038},{"date":"2021-01-08","current":-97.077701,"twenty":-23.97186,"median":-3.789176,"eighty":65.318147,"marketCap":8208210867},{"date":"2021-01-15","current":-98.122854,"twenty":-24.454235,"median":-3.789176,"eighty":65.318147,"marketCap":8296581690},{"date":"2021-01-22","current":-99.739195,"twenty":-24.744147,"median":-3.789176,"eighty":65.318147,"marketCap":8433248195},{"date":"2021-01-29","current":-94.726725,"twenty":-24.828261,"median":-3.789176,"eighty":65.318147,"marketCap":8009428769},{"date":"2021-02-05","current":-91.510733,"twenty":-25.440997,"median":-3.789176,"eighty":65.318147,"marketCap":9390099332},{"date":"2021-02-12","current":-89.21462,"twenty":-26.042831,"median":-3.805477,"eighty":65.318147,"marketCap":9154490562},{"date":"2021-02-19","current":-90.53969,"twenty":-26.322299,"median":-3.843641,"eighty":65.318147,"marketCap":9290458619},{"date":"2021-02-26","current":-80.576379,"twenty":-26.916244,"median":-3.873833,"eighty":65.318147,"marketCap":8268103380},{"date":"2021-03-05","current":-69.79375,"twenty":-28.366158,"median":-3.907377,"eighty":65.320437,"marketCap":7161676290},{"date":"2021-03-12","current":-73.576774,"twenty":-29.531319,"median":-3.935488,"eighty":65.320437,"marketCap":7549859903},{"date":"2021-03-19","current":-68.175344,"twenty":-30.12048,"median":-3.970626,"eighty":65.320437,"marketCap":6995608434},{"date":"2021-03-26","current":-63.674153,"twenty":-30.547075,"median":-3.999327,"eighty":65.318147,"marketCap":6533732209},{"date":"2021-04-01","current":-67.841548,"twenty":-30.954671,"median":-4.016306,"eighty":65.318147,"marketCap":6961356938},{"date":"2021-04-09","current":-62.86495,"twenty":-31.342858,"median":-4.012792,"eighty":65.320437,"marketCap":6450698281},{"date":"2021-04-16","current":-68.42822,"twenty":-31.889554,"median":-4.012792,"eighty":65.320437,"marketCap":7021556536},{"date":"2021-04-23","current":-72.413545,"twenty":-32.415644,"median":-4.012792,"eighty":65.320437,"marketCap":7430498631},{"date":"2021-04-30","current":-73.597004,"twenty":-32.808234,"median":-4.012792,"eighty":65.320437,"marketCap":7551935751},{"date":"2021-05-07","current":-63.043178,"twenty":-45.932572,"median":-4.012792,"eighty":65.320437,"marketCap":6909154068},{"date":"2021-05-14","current":-69.168946,"twenty":-56.438632,"median":-4.033875,"eighty":65.320437,"marketCap":7580501519},{"date":"2021-05-21","current":-70.498571,"twenty":-57.863948,"median":-4.083069,"eighty":65.320437,"marketCap":7726220345},{"date":"2021-05-28","current":-68.950508,"twenty":-58.296058,"median":-4.111179,"eighty":65.320437,"marketCap":7556561997},{"date":"2021-06-04","current":-72.312558,"twenty":-58.476641,"median":-4.111179,"eighty":65.320437,"marketCap":7925022458},{"date":"2021-06-11","current":-84.250683,"twenty":-59.153827,"median":-4.111179,"eighty":65.320437,"marketCap":9233369349},{"date":"2021-06-18","current":-81.335007,"twenty":-59.54079,"median":-4.132262,"eighty":65.320437,"marketCap":8913828780},{"date":"2021-06-25","current":-85.779751,"twenty":-60.082539,"median":-4.188484,"eighty":65.320437,"marketCap":9400946000},{"date":"2021-07-02","current":-59.956551,"twenty":-60.959657,"median":-4.346124,"eighty":65.320437,"marketCap":6570878221},{"date":"2021-07-09","current":-63.764974,"twenty":-61.333721,"median":-4.547082,"eighty":65.320437,"marketCap":6988258574},{"date":"2021-07-16","current":-60.24147,"twenty":-61.430462,"median":-4.684632,"eighty":65.320437,"marketCap":6602103684},{"date":"2021-07-23","current":-64.933144,"twenty":-61.694887,"median":-4.836997,"eighty":65.320437,"marketCap":7116282972},{"date":"2021-07-30","current":-65.806897,"twenty":-62.139895,"median":-5.073506,"eighty":65.320437,"marketCap":7212041058},{"date":"2021-08-06","current":-53.65037,"twenty":-62.324426,"median":-5.25661,"eighty":65.320437,"marketCap":6754957196},{"date":"2021-08-13","current":-50.11453,"twenty":-62.324426,"median":-5.302386,"eighty":65.320437,"marketCap":6309770173},{"date":"2021-08-20","current":-49.625972,"twenty":-62.324426,"median":-5.37105,"eighty":65.320437,"marketCap":6248257212},{"date":"2021-08-27","current":-54.710294,"twenty":-62.324426,"median":-5.386309,"eighty":65.320437,"marketCap":6888409043},{"date":"2021-09-03","current":-55.935832,"twenty":-62.324426,"median":-5.401568,"eighty":65.320437,"marketCap":7042712742},{"date":"2021-09-10","current":-52.987918,"twenty":-62.324426,"median":-5.401568,"eighty":65.320437,"marketCap":6671549791},{"date":"2021-09-17","current":-53.7663,"twenty":-62.324426,"median":-5.500749,"eighty":65.320437,"marketCap":6769553492},{"date":"2021-09-24","current":-54.130649,"twenty":-62.324426,"median":-5.561784,"eighty":65.320437,"marketCap":6815427564},{"date":"2021-10-01","current":-51.836907,"twenty":-62.324426,"median":-9.576545,"eighty":65.320437,"marketCap":6526629425},{"date":"2021-10-08","current":-49.957198,"twenty":-62.324426,"median":-10.599494,"eighty":65.320437,"marketCap":6289960914},{"date":"2021-10-15","current":-54.78482,"twenty":-62.324426,"median":-12.617221,"eighty":65.320437,"marketCap":6897792376},{"date":"2021-10-22","current":-54.677172,"twenty":-62.324426,"median":-13.619752,"eighty":65.320437,"marketCap":6884238673},{"date":"2021-10-29","current":-52.847147,"twenty":-62.324426,"median":-14.182147,"eighty":65.320437,"marketCap":6653825717},{"date":"2021-11-05","current":-66.849736,"twenty":-62.691778,"median":-14.893608,"eighty":65.320437,"marketCap":8416849736},{"date":"2021-11-12","current":-61.227171,"twenty":-62.849328,"median":-15.49945,"eighty":65.320437,"marketCap":7708929388},{"date":"2021-11-19","current":-58.883745,"twenty":-62.849328,"median":-15.600362,"eighty":65.320437,"marketCap":7413875694},{"date":"2021-11-26","current":-53.447273,"twenty":-62.849328,"median":-15.768963,"eighty":65.320437,"marketCap":7527941490},{"date":"2021-12-03","current":-50.092904,"twenty":-62.849328,"median":-16.040498,"eighty":65.320437,"marketCap":7055485290},{"date":"2021-12-10","current":-52.000145,"twenty":-62.849328,"median":-16.358374,"eighty":65.320437,"marketCap":7324116359},{"date":"2021-12-17","current":-51.695877,"twenty":-62.849328,"median":-16.725153,"eighty":65.320437,"marketCap":7281260819},{"date":"2021-12-23","current":-52.133726,"twenty":-62.849328,"median":-16.774057,"eighty":65.320437,"marketCap":7342930987},{"date":"2021-12-31","current":-49.202363,"twenty":-62.849328,"median":-17.043029,"eighty":65.320437,"marketCap":6930054440},{"date":"2022-01-07","current":-43.747802,"twenty":-62.849328,"median":-17.532069,"eighty":65.318147,"marketCap":6161790486},{"date":"2022-01-14","current":-42.901789,"twenty":-62.849328,"median":-17.703232,"eighty":65.318147,"marketCap":6042631179},{"date":"2022-01-21","current":-37.729233,"twenty":-62.849328,"median":-17.9233,"eighty":65.318147,"marketCap":5314086994},{"date":"2022-01-28","current":-37.50079,"twenty":-62.849328,"median":-18.094464,"eighty":65.318147,"marketCap":5281911207},{"date":"2022-02-04","current":-28.67194,"twenty":-62.849328,"median":-18.47347,"eighty":65.318147,"marketCap":5246620871},{"date":"2022-02-11","current":-29.190628,"twenty":-62.849328,"median":-18.89431,"eighty":65.318147,"marketCap":5341534615},{"date":"2022-02-18","current":-25.502177,"twenty":-62.849328,"median":-19.299259,"eighty":65.318147,"marketCap":4666592433},{"date":"2022-02-25","current":-25.352334,"twenty":-62.849328,"median":-19.511471,"eighty":65.318147,"marketCap":4639172906},{"date":"2022-03-04","current":-24.735671,"twenty":-62.849328,"median":-19.873469,"eighty":65.318147,"marketCap":4526331010},{"date":"2022-03-11","current":-24.078666,"twenty":-62.849328,"median":-20.265536,"eighty":65.318147,"marketCap":4406106934},{"date":"2022-03-18","current":-27.30606,"twenty":-62.849328,"median":-20.427007,"eighty":65.318147,"marketCap":4996681344},{"date":"2022-03-25","current":-25.421493,"twenty":-62.849328,"median":-20.792261,"eighty":65.318147,"marketCap":4651828072},{"date":"2022-04-01","current":-28.354963,"twenty":-62.849328,"median":-20.994442,"eighty":65.318147,"marketCap":5188618027},{"date":"2022-04-08","current":-27.807459,"twenty":-62.849328,"median":-21.14622,"eighty":65.318147,"marketCap":5088431297},{"date":"2022-04-14","current":-27.012137,"twenty":-62.849328,"median":-21.291767,"eighty":65.318147,"marketCap":4942896888},{"date":"2022-04-22","current":-24.585828,"twenty":-62.849328,"median":-21.677169,"eighty":65.318147,"marketCap":4498911484},{"date":"2022-04-29","current":-23.692531,"twenty":-62.849328,"median":-21.85137,"eighty":65.318147,"marketCap":4335448924},{"date":"2022-05-06","current":-21.277749,"twenty":-62.849328,"median":-22.070043,"eighty":65.318147,"marketCap":3893572714},{"date":"2022-05-13","current":-29.922841,"twenty":-62.849328,"median":-22.230837,"eighty":65.318147,"marketCap":3345493368},{"date":"2022-05-20","current":-34.24482,"twenty":-62.849328,"median":-22.60735,"eighty":65.318147,"marketCap":3828707802},{"date":"2022-05-27","current":-32.343906,"twenty":-62.849328,"median":-22.835097,"eighty":65.318147,"marketCap":3616178040},{"date":"2022-06-03","current":-32.968086,"twenty":-62.849328,"median":-23.022811,"eighty":65.318147,"marketCap":3685963932},{"date":"2022-06-10","current":-28.863626,"twenty":-62.849328,"median":-23.265009,"eighty":65.318147,"marketCap":3227068824},{"date":"2022-06-17","current":-27.539606,"twenty":-62.849328,"median":-23.436785,"eighty":65.318147,"marketCap":3079038144},{"date":"2022-06-24","current":-32.589795,"twenty":-62.849328,"median":-23.562992,"eighty":65.320437,"marketCap":3643669452},{"date":"2022-07-01","current":-34.008387,"twenty":-62.849328,"median":-23.735995,"eighty":65.320437,"marketCap":3802273752},{"date":"2022-07-08","current":-39.465239,"twenty":-62.849328,"median":-23.824971,"eighty":65.320437,"marketCap":4412371626},{"date":"2022-07-15","current":-40.477169,"twenty":-62.849328,"median":-23.891697,"eighty":65.320437,"marketCap":4525509360},{"date":"2022-07-22","current":-40.354224,"twenty":-62.849328,"median":-23.943598,"eighty":65.320437,"marketCap":4511763654},{"date":"2022-07-29","current":-40.221822,"twenty":-62.849328,"median":-24.254281,"eighty":65.320437,"marketCap":4496960586},{"date":"2022-08-05","current":-31.604916,"twenty":-62.849328,"median":-24.559153,"eighty":65.320437,"marketCap":4864818339},{"date":"2022-08-12","current":-32.519506,"twenty":-62.849328,"median":-24.631934,"eighty":65.320437,"marketCap":5005597460},{"date":"2022-08-19","current":-29.301251,"twenty":-62.849328,"median":-24.78754,"eighty":65.320437,"marketCap":4510224313},{"date":"2022-08-26","current":-27.547714,"twenty":-62.849328,"median":-24.830151,"eighty":65.320437,"marketCap":4240309457},{"date":"2022-09-02","current":-27.107611,"twenty":-62.849328,"median":-25.139096,"eighty":65.320437,"marketCap":4172566121},{"date":"2022-09-09","current":-26.523099,"twenty":-62.849328,"median":-25.306228,"eighty":65.320437,"marketCap":4082594502},{"date":"2022-09-16","current":-23.786207,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3661315630},{"date":"2022-09-23","current":-21.269366,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3273908425},{"date":"2022-09-30","current":-22.727208,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3498308227},{"date":"2022-10-07","current":-21.743852,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3346944210},{"date":"2022-10-14","current":-22.018917,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3389283795},{"date":"2022-10-21","current":-22.961013,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3534296874},{"date":"2022-10-28","current":-24.666413,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3796802302},{"date":"2022-11-04","current":-23.35298,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3594630783},{"date":"2022-11-11","current":-23.71744,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3650730733},{"date":"2022-11-18","current":-21.124957,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3251680143},{"date":"2022-11-25","current":-20.28601,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3122544408},{"date":"2022-12-02","current":-20.428904,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3596774147},{"date":"2022-12-09","current":-18.207193,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3205613033},{"date":"2022-12-16","current":-19.12839,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3367801787},{"date":"2022-12-23","current":-23.060036,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":4060019152},{"date":"2022-12-30","current":-24.420759,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":4299592084},{"date":"2023-01-06","current":-22.506114,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3962493888},{"date":"2023-01-13","current":-22.168943,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3903130684},{"date":"2023-01-20","current":-20.326549,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3578753174},{"date":"2023-01-27","current":-20.236235,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3562852316},{"date":"2023-02-03","current":-22.267052,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3920403974},{"date":"2023-02-10","current":-23.21593,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3587232598},{"date":"2023-02-17","current":-23.657537,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3655468001},{"date":"2023-02-24","current":-22.872457,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3534160618},{"date":"2023-03-03","current":-22.676187,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3503833773},{"date":"2023-03-10","current":-18.442364,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2849640388},{"date":"2023-03-17","current":-17.033427,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2631936960},{"date":"2023-03-24","current":-17.026417,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":2630853859},{"date":"2023-03-31","current":-17.804487,"twenty":-62.849328,"median":-25.329281,"eighty":65.318147,"marketCap":2751078140},{"date":"2023-04-06","current":-17.713362,"twenty":-62.849328,"median":-25.329281,"eighty":65.318147,"marketCap":2736997819},{"date":"2023-04-14","current":-21.379404,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3303459971},{"date":"2023-04-21","current":-20.972845,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3240640076},{"date":"2023-04-28","current":-24.505704,"twenty":-62.849328,"median":-25.352334,"eighty":65.320437,"marketCap":3786523298},{"date":"2023-05-05","current":-28.503078,"twenty":-62.849328,"median":-25.406021,"eighty":65.320437,"marketCap":4281361861},{"date":"2023-05-12","current":-28.524429,"twenty":-62.849328,"median":-25.564592,"eighty":65.322728,"marketCap":4284568873},{"date":"2023-05-19","current":-25.820017,"twenty":-62.849328,"median":-25.767729,"eighty":65.327309,"marketCap":3878347273},{"date":"2023-05-26","current":-23.891344,"twenty":-62.849498,"median":-25.820017,"eighty":65.341771,"marketCap":3588647132},{"date":"2023-06-02","current":-24.6742,"twenty":-62.849668,"median":-25.85766,"eighty":65.356234,"marketCap":3706237596},{"date":"2023-06-09","current":-25.407238,"twenty":-62.849668,"median":-25.915884,"eighty":65.356234,"marketCap":3816345029},{"date":"2023-06-16","current":-25.435706,"twenty":-62.849668,"median":-25.915884,"eighty":65.356234,"marketCap":3820621046},{"date":"2023-06-23","current":-25.300485,"twenty":-62.849839,"median":-25.72783,"eighty":65.370696,"marketCap":3800309966},{"date":"2023-06-30","current":-25.570926,"twenty":-62.850009,"median":-25.674346,"eighty":65.385159,"marketCap":3840932126},{"date":"2023-07-07","current":-24.581681,"twenty":-62.850179,"median":-25.548283,"eighty":65.399621,"marketCap":3692340541},{"date":"2023-07-14","current":-24.546097,"twenty":-62.853133,"median":-25.4286,"eighty":65.437987,"marketCap":3686995520},{"date":"2023-07-21","current":-24.780953,"twenty":-62.853133,"median":-25.333526,"eighty":65.437987,"marketCap":3722272659},{"date":"2023-07-28","current":-25.499758,"twenty":-62.853133,"median":-25.303356,"eighty":65.437987,"marketCap":3830242084},{"date":"2023-08-04","current":-23.001735,"twenty":-62.853133,"median":-25.189784,"eighty":65.437987,"marketCap":3455021606},{"date":"2023-08-11","current":-17.14665,"twenty":-62.853133,"median":-25.145063,"eighty":65.437987,"marketCap":3105378341},{"date":"2023-08-18","current":-17.176244,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":3110737987},{"date":"2023-08-25","current":-16.596205,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":3005688944},{"date":"2023-09-01","current":-16.359455,"twenty":-62.853133,"median":-25.111888,"eighty":65.437987,"marketCap":2962811783},{"date":"2023-09-08","current":-17.886495,"twenty":-62.853133,"median":-25.073568,"eighty":65.437987,"marketCap":3239369468},{"date":"2023-09-15","current":-18.075895,"twenty":-62.856087,"median":-25.01581,"eighty":65.476352,"marketCap":3273671196},{"date":"2023-09-22","current":-16.116786,"twenty":-62.856087,"median":-24.951758,"eighty":65.476352,"marketCap":2918862694},{"date":"2023-09-29","current":-15.939223,"twenty":-62.856087,"median":-24.830151,"eighty":65.476352,"marketCap":2886704823},{"date":"2023-10-06","current":-15.122434,"twenty":-62.859042,"median":-24.823525,"eighty":65.514718,"marketCap":2738778620},{"date":"2023-10-13","current":-15.317753,"twenty":-62.859042,"median":-24.823525,"eighty":65.514718,"marketCap":2774152277},{"date":"2023-10-20","current":-15.004059,"twenty":-62.861996,"median":-24.825913,"eighty":65.553083,"marketCap":2717340040},{"date":"2023-10-23","current":-15.057327,"twenty":-62.861996,"median":-24.825913,"eighty":65.553083,"marketCap":2726987401},{"date":"2023-11-03","current":-15.483478,"twenty":-62.913621,"median":-24.830151,"eighty":65.661983,"marketCap":2804166290},{"date":"2023-11-10","current":-15.826766,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2866338172},{"date":"2023-11-17","current":-15.424291,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2793447000},{"date":"2023-11-24","current":-17.235431,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":3121457277},{"date":"2023-12-01","current":-11.082764,"twenty":-62.913621,"median":-24.825913,"eighty":65.661983,"marketCap":2275014400},{"date":"2023-12-08","current":-12.837959,"twenty":-62.897398,"median":-24.823525,"eighty":65.638472,"marketCap":2635312111},{"date":"2023-12-15","current":-14.941857,"twenty":-62.897398,"median":-24.799067,"eighty":65.638472,"marketCap":3067189595},{"date":"2023-12-22","current":-15.051762,"twenty":-62.897398,"median":-24.799067,"eighty":65.638472,"marketCap":3089750359},{"date":"2023-12-29","current":-16.224082,"twenty":-62.913621,"median":-24.810593,"eighty":65.661983,"marketCap":3330398510},{"date":"2024-01-05","current":-20.727623,"twenty":-62.929845,"median":-24.815865,"eighty":65.685495,"marketCap":4254862911},{"date":"2024-01-12","current":-22.510451,"twenty":-62.929845,"median":-24.780146,"eighty":65.685495,"marketCap":4620832875},{"date":"2024-01-19","current":-19.905242,"twenty":-62.946069,"median":-24.739411,"eighty":65.709006,"marketCap":4086048483},{"date":"2024-01-26","current":-20.061314,"twenty":-62.929845,"median":-24.737541,"eighty":65.685495,"marketCap":4118086258},{"date":"2024-02-02","current":-19.419562,"twenty":-62.929845,"median":-24.715611,"eighty":65.685495,"marketCap":3986350531},{"date":"2024-02-09","current":-12.877492,"twenty":-62.929845,"median":-24.670306,"eighty":65.685495,"marketCap":3822219796},{"date":"2024-02-16","current":-12.343191,"twenty":-62.929845,"median":-24.583754,"eighty":65.685495,"marketCap":3663631746},{"date":"2024-02-23","current":-12.606167,"twenty":-62.929845,"median":-24.5259,"eighty":65.685495,"marketCap":3741686802},{"date":"2024-03-01","current":-13.39927,"twenty":-62.849839,"median":-24.403759,"eighty":65.661983,"marketCap":3977090939},{"date":"2024-03-08","current":-13.858435,"twenty":-62.78865,"median":-24.183136,"eighty":65.661983,"marketCap":4113377544},{"date":"2024-03-15","current":-11.445732,"twenty":-62.78865,"median":-24.078666,"eighty":65.661983,"marketCap":3397253381},{"date":"2024-03-22","current":-11.783844,"twenty":-62.78865,"median":-23.934586,"eighty":65.661983,"marketCap":3497609882},{"date":"2024-03-28","current":-11.980033,"twenty":-62.78865,"median":-23.867826,"eighty":65.661983,"marketCap":3555841431},{"date":"2024-04-05","current":-10.898908,"twenty":-62.771965,"median":-23.697907,"eighty":65.685495,"marketCap":3234948424},{"date":"2024-04-12","current":-10.719416,"twenty":-62.450545,"median":-23.597561,"eighty":65.685495,"marketCap":3181672751},{"date":"2024-04-19","current":-9.437928,"twenty":-62.450545,"median":-23.514443,"eighty":65.685495,"marketCap":2801309225},{"date":"2024-04-26","current":-9.129035,"twenty":-62.427752,"median":-23.37361,"eighty":65.661983,"marketCap":2709625509},{"date":"2024-05-03","current":-10.072411,"twenty":-62.427752,"median":-23.21593,"eighty":65.661983,"marketCap":2989632534},{"date":"2024-05-10","current":-6.482305,"twenty":-62.427752,"median":-23.186475,"eighty":65.370696,"marketCap":3068567760},{"date":"2024-05-17","current":-6.595323,"twenty":-62.427752,"median":-23.186475,"eighty":64.679241,"marketCap":3105005750},{"date":"2024-05-24","current":-6.508265,"twenty":-62.427752,"median":-23.186475,"eighty":63.492771,"marketCap":3064019674},{"date":"2024-05-31","current":-6.009659,"twenty":-62.427752,"median":-23.186475,"eighty":62.516156,"marketCap":2829281239},{"date":"2024-06-07","current":-6.513541,"twenty":-62.427752,"median":-23.186475,"eighty":61.77678,"marketCap":3066503678},{"date":"2024-06-14","current":-6.991043,"twenty":-62.450545,"median":-23.188804,"eighty":61.001953,"marketCap":3291306095},{"date":"2024-06-21","current":-6.27611,"twenty":-62.473339,"median":-23.191133,"eighty":60.436538,"marketCap":2954723471},{"date":"2024-06-28","current":-6.777354,"twenty":-62.570212,"median":-23.208812,"eighty":59.933947,"marketCap":3190703908},{"date":"2024-07-05","current":-6.61379,"twenty":-62.570212,"median":-23.208812,"eighty":58.878506,"marketCap":3113699766},{"date":"2024-07-12","current":-7.452716,"twenty":-62.570212,"median":-23.208812,"eighty":57.044321,"marketCap":3508656497},{"date":"2024-07-15","current":-7.415782,"twenty":-62.570212,"median":-23.208812,"eighty":56.809508,"marketCap":3491268465},{"date":"2024-08-02","current":-7.244303,"twenty":-62.781052,"median":-23.464332,"eighty":50.761782,"marketCap":3410538315},{"date":"2024-08-09","current":-5.966088,"twenty":-62.781052,"median":-23.464332,"eighty":47.94868,"marketCap":3213549832},{"date":"2024-08-16","current":-5.229847,"twenty":-62.781052,"median":-23.464332,"eighty":-5.237233,"marketCap":2816984108},{"date":"2024-08-23","current":-5.624509,"twenty":-62.781052,"median":-23.464332,"eighty":-5.400175,"marketCap":3029563227},{"date":"2024-08-30","current":-5.557578,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2993511797},{"date":"2024-09-06","current":-5.366017,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2890330120},{"date":"2024-09-13","current":-4.670166,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2515519569},{"date":"2024-09-20","current":-4.879037,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2628024892},{"date":"2024-09-27","current":-4.528226,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2439065675},{"date":"2024-10-04","current":-4.350513,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2343342914},{"date":"2024-10-11","current":-4.085097,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2200380349},{"date":"2024-10-18","current":-4.809798,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2590730310},{"date":"2024-10-25","current":-4.599773,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2477603410},{"date":"2024-10-31","current":-4.548998,"twenty":-62.781052,"median":-23.464332,"eighty":-5.611123,"marketCap":2450254050},{"date":"2024-11-08","current":-4.936736,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2659103710},{"date":"2024-11-15","current":-4.941352,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2661590016},{"date":"2024-11-22","current":-4.218959,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2272483208},{"date":"2024-11-29","current":-5.402946,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":3239028525},{"date":"2024-12-06","current":-4.628725,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2774888056},{"date":"2024-12-13","current":-4.595514,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2754978545},{"date":"2024-12-20","current":-4.04754,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2426471619},{"date":"2024-12-27","current":-4.053767,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2430204652},{"date":"2025-01-03","current":-4.078674,"twenty":-62.784851,"median":-23.466049,"eighty":-5.670207,"marketCap":2445136785},{"date":"2025-01-10","current":-4.099431,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2457580229},{"date":"2025-01-17","current":-3.947908,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2366743086},{"date":"2025-01-24","current":-4.468899,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2679073536},{"date":"2025-01-31","current":-4.199063,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2517308761},{"date":"2025-02-07","current":-4.27277,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2561495982},{"date":"2025-02-14","current":-3.766894,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2409734901},{"date":"2025-02-21","current":-4.131559,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2643016406},{"date":"2025-02-28","current":-3.733384,"twenty":-62.78865,"median":-23.467766,"eighty":-5.708058,"marketCap":2388298222},{"date":"2025-03-07","current":-3.483047,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":2228153621},{"date":"2025-03-14","current":-2.970544,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1900298532},{"date":"2025-03-21","current":-2.978429,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1905342457},{"date":"2025-03-28","current":-2.720206,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1740153931},{"date":"2025-04-04","current":-2.377224,"twenty":-62.792449,"median":-23.478536,"eighty":-5.739251,"marketCap":1520743218}],"updateTime":1743865642564}}}